• Vasileios Ragos, Omer Yazici, Yasemin Guzle Adas, Esra Kekilli, Tamer Calikoglu, Muzaffer Bedri Altundag, Ali Riza Ucer, Gulcin Ertas, Sema Durmus Duzgun, Kenan Ozbagi, Atilla Demirkasimoglu, Erdal Demir, Bora Aslan, and Bektas Kaya.
• Department of Maxillofacial Surgery, Medical School, University of Ioannina, Greece.
• J Buon. 2018 Jul 1; 23 (4): 1169-1173.

PurposeDefinitive radiotherapy is a treatment option for patients with inoperable meningiomas. The purpose of this study was to evaluate the results of stereotactic radiotherapy as first-line treatment for intracranial meningiomas that were diagnosed radiologically.MethodsBetween January 2010 and June 2016, 56 patients with intracranial meningioma treated with Cyberknife- based Stereotactic Radiosurgery (SRS) or hypofractionated stereotactic radiotherapy (hFSRT) were included. The median prescribed radiation dose was 16 Gy (range 13-18) for SRS and 25 Gy (range 18-33) for hFSRT. hFSRT doses were delivered in 3 to 5 fractions.ResultsMedian follow-up was 58 months (range 6-97). Overall survival (OS) for the whole group was 89.2%; for SRS group it was 100% and for hFSRT group 87.5% (p=0.29). Progression free survival (PFS) for the whole group was 89.3%; for SRS group it was 87.5% and for hFSRT 89.5% at 5 years (p=0.93).ConclusionSRS and hFSRT were effective with excellent local control rates and they can be an alternative treatment option for patients with inoperable meningiomas.

18 keywords...

hide…